NCT06953323 2025-08-13
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT06010212 2023-08-24
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT01712919 2014-03-24
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
Jiangsu Cancer Institute & Hospital
Phase 1/2 Completed